Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis (Fibro-ALS)
Primary Purpose
Sporadic Amyotrophic Lateral Sclerosis
Status
Unknown status
Phase
Early Phase 1
Locations
Study Type
Interventional
Intervention
Skin Biopsy
Sponsored by
About this trial
This is an interventional basic science trial for Sporadic Amyotrophic Lateral Sclerosis focused on measuring Bioenergetics, Protein Metabolism, Sporadic Amyotrophic Lateral Sclerosis
Eligibility Criteria
Inclusion criteria :
- a free signed an written consent
- aged between 18 and 80 years old
- ALS defined by El Escorial Criteria
- normal neurological examination
Exclusion criteria:
- comorbidity or treatment susceptible to impact on metabolism
- differential diagnosis suspected, early and late forms (<6 month > 3 years)
- ALS not defined by El Escorial Criteria
- withdrawal of consent to participate
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
Patients
Controls
Arm Description
ALS defined by El Escorial Criteria.
Asymptomatic subjects with normal examination.
Outcomes
Primary Outcome Measures
Kinetics of fibroblast growth
The growth rates of the fibroblast lines
Secondary Outcome Measures
Mitochondrial metabolism
the breath parameters of fibroblast will be precisely studied by oxygraphy, a method consisting in measuring the oxygen consumption rates of fibroblasts in different metabolic phases
Protéic metabolism
The presence of intracytoplasmic inclusion of target protein will be sought.
stress in senescence answer
the answer due to the stress of cell lines in hypoxia and nutritionnal lack will be studied.
Full Information
NCT ID
NCT02969759
First Posted
November 4, 2016
Last Updated
November 22, 2016
Sponsor
University Hospital, Angers
1. Study Identification
Unique Protocol Identification Number
NCT02969759
Brief Title
Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis
Acronym
Fibro-ALS
Official Title
Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis
Study Type
Interventional
2. Study Status
Record Verification Date
November 2016
Overall Recruitment Status
Unknown status
Study Start Date
November 2016 (undefined)
Primary Completion Date
November 2017 (Anticipated)
Study Completion Date
November 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Angers
4. Oversight
5. Study Description
Brief Summary
INTRODUCTION: Amyotrophic Lateral Sclerosis (ALS) is a degenerative disease of the motor neurones of the brain and the spinal cord. The pathophysiological mechanisms of the disease remain unknown. The average age of onset of ALS is about 60 years old, and the mean survival of patients is about 2 years. The disease is responsible for a progressive paralysis leading to death from respiratory failure. The only treatment available is the Riluzole, with a very modest efficiency on the progression of the disease. ALS is the third neurodegenerative disease, affecting 6000 persons in France, 150 000 in the world. Among the protagonists involved in the occurrence of the disease, mitochondrial perturbations and protein accumulations seem to be central elements.
OBJECTIVES: To precise the implication of energy and protein metabolism in the sporadic forms of ALS, to identify potential biomarkers of the disease and to test new therapies.
METHODS: The investigators will study cell growth, bioenergetics, mitochondrial dynamics, free-radicals production, presence of cytoplasmic inclusions, cytoskeleton structure and stress response in primary skin fibroblasts obtained from sporadic ALS patients. The study will be conducted over a period of three years in 3 centres specialized respectively in motor neuron diseases, mitochondrial metabolism and neuronal cytoskeleton.
PROSPECTS: If the investigators achieve to identify differences between ALS fibroblasts and controls, the results will be key elements to reinforce the hypothesis of a systemic disease with an important metabolic participation, to better define ALS pathophysiological mechanisms, to find potential biomarkers and to test new therapies.
Detailed Description
The investigators will study fibroblasts derived from sporadic ALS patients.
Clinical parameters will be collected such as sex, age, age of onset, clinical presentation, electrophysiological an respiratory parameters, treatments.
Patients and controls derived fibroblasts will be amplified and cultivated from skin biopsies.
Primary fibroblast cell cultures will be derived from skin biopsies obtained from control subjects and from the patients after obtaining written consent. Amplifications will be performed, from passage 1 to 6, allowing the time for cell cryopreservation of 10 samples per cell line. All experiments will be conducted on cells with similar passage numbers, ranging from 6 to 25, to avoid artefacts due to senescence.
Cell growth of each line will be monitored with the IncuCyte ZOOM® system (Essen Biosciences), a microscope gantry that resides in a cell incubator, and a networked external controller hard drive that gathers and processes image data. Cell growth will be automatically calculated at each time point using the relative cell density (ratio of the occupied area to the total area of the acquired regions).
The respiratory parameters of the fibroblasts will be monitored precisely with an high resolution oxygraph (OROBOROS). Enzymatic activity of each complex of the mitochondrial respiratory chain will be measured by spectrometry, and the mitochondrial membrane potential will be studied with fluorescence microscopy (TMRM probe). The investigators will also study mitochondrial dynamics and the architecture of mitochondrial network with fluorescence microscopy and super-resolution microscopy (SRM, Roper). The production of free radicals will be estimated with probes sensitive to oxidative stress. Finally, a metabolomic study (mass spectrometry QTRAP LC/MS/MS 5500 ABSciex) will be performed to characterise precisely the metabolites in the cells and to assess their metabolic profile.
The investigators will search for protein inclusions (intermediate filaments, TDP43, FUS, ubiquitin) with immuno-fluorescence technics. Western Blots will be performed to study the protein metabolism. The architecture of the cytoskeleton will be analysed in SRM and fluorescence microscopy, and the investigators will try to transfect fibroblasts in order to express Neurofilaments and study the consequences on the cytoskeleton and protein metabolism.
The investigators will study the response of the cells to the stress (hypoxia SCI-tive Dual, starvation), and to senescence (high passage numbers).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sporadic Amyotrophic Lateral Sclerosis
Keywords
Bioenergetics, Protein Metabolism, Sporadic Amyotrophic Lateral Sclerosis
7. Study Design
Primary Purpose
Basic Science
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
30 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Patients
Arm Type
Other
Arm Description
ALS defined by El Escorial Criteria.
Arm Title
Controls
Arm Type
Other
Arm Description
Asymptomatic subjects with normal examination.
Intervention Type
Other
Intervention Name(s)
Skin Biopsy
Primary Outcome Measure Information:
Title
Kinetics of fibroblast growth
Description
The growth rates of the fibroblast lines
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Mitochondrial metabolism
Description
the breath parameters of fibroblast will be precisely studied by oxygraphy, a method consisting in measuring the oxygen consumption rates of fibroblasts in different metabolic phases
Time Frame
24 hours
Title
Protéic metabolism
Description
The presence of intracytoplasmic inclusion of target protein will be sought.
Time Frame
24 hours
Title
stress in senescence answer
Description
the answer due to the stress of cell lines in hypoxia and nutritionnal lack will be studied.
Time Frame
24 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria :
a free signed an written consent
aged between 18 and 80 years old
ALS defined by El Escorial Criteria
normal neurological examination
Exclusion criteria:
comorbidity or treatment susceptible to impact on metabolism
differential diagnosis suspected, early and late forms (<6 month > 3 years)
ALS not defined by El Escorial Criteria
withdrawal of consent to participate
12. IPD Sharing Statement
Learn more about this trial
Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis
We'll reach out to this number within 24 hrs